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Copper is the trace element essential for the proper func-
tioning of the cells because of its role as cofactor of many
crucial enzymes, such as cytochrome c oxidase, superoxide
dismutase and lysyl oxidase. Cellular transport system
ensures the exact distribution of copper throughout the
body and consequently its malfunction could lead to
serious medical conditions, such as Menkes and Wilson
disease. Apart from copper transport this system is used
to move platinum and its derivates through the cell and
body- including the widely used chemotherapeutic drug
cisplatin. It is therefore believed that polymorphic variants
in genes encoding the importer (CTR1) and intracellular
exporters via the TNG network (ATP7A and ATP7B)
could alter the drug availability and its therapeutic concen-
tration. As the result of such alterations cisplatin resis-
tance or oversensitivity could be developed leading to
cancer therapy failure and/or serious deterioration of
patients’ condition. Similar consequences could also be
the result of modifications in genes encoding multidrug
and toxin extrusion proteins (MATE family). These efflux
transporters are not the part of the main copper transport
system, but are crucial for efficient elimination of toxins,
including copper and platinum drugs, in liver and kidneys.
Impact of genetic polymorphisms in copper transport
systems on the response to cancer treatment was analysed
in the group of 129 women diagnosed with epithelial ovar-
ian cancer receiving cisplatin-based first-line chemother-
apy. For this study we selected 11 functional variants in
CTR1, ATP7A, ATP7B, MATE1 and MATE2-K genes.
The results show that decrease of platinum importer
CTR1 expression, as the consequence of intronic
rs12686377 variant, leads to platinum-resistant phenotype
and significantly rises the risk of death (HR 2.62; p =
0.005). On the other hand three functional variants in
ATP7B transporter gene are responsible for treatment-
related, both overall and early, neutropenia. Furthermore
the risk of bone marrow damage increases with the accu-
mulation of unfavourable genotypes, reaching OR 7.89 for
overall and OR 27.33 for early neutropenia. Chemother-
apy-induced liver damage seems to correlate with
rs2289669 variant in hepatocytes guardian MATE1, which
in combination with polymorphism p.Arg72Pro in TP53
gene is responsible for over 17-fold increase of hepatotoxi-
city risk.
The results indicate that efficient platinum influx to the
cells is crucial for positive reaction to treatment and
patients’ longer overall survival. Cisplatin-induced toxicity
on the other hand seems to be dependent on the manage-
ment of the drug’s concentration- by both intracellular
transport (ATP7B) and extrusion (MATE1) systems.
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